| Pharmaceutical Information |
| Drug Name |
Trospium |
| Drug ID |
BADD_D02305 |
| Description |
Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably.[L6208] An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination.[L6208] Trospium is manufactured by _Indevus Pharmaceutical Inc._ and was granted FDA approval in 2007.[L6211] |
| Indications and Usage |
For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency, detrusor instability and frequency of micturition. |
| Marketing Status |
approved |
| ATC Code |
G04BD09 |
| DrugBank ID |
DB00209
|
| KEGG ID |
D01103
|
| MeSH ID |
C003330
|
| PubChem ID |
5284632
|
| TTD Drug ID |
D05TIB
|
| NDC Product Code |
Not Available |
| UNII |
T4Y8ORK057
|
| Synonyms |
trospium chloride | azoniaspiro compound XVII | azoniaspiro(3 alpha-benziloyloxynortropane-8,1'- pyrrolidine) chloride | Spasmex | Uraton | Spasmolyt | Spasmo-Urgenin TC | Spasmo-lyt | Spasmo-Rhoival TC | Trospi | Ceris | Uraplex | Spasmo-Urgenin |
|
| Chemical Information |
| Molecular Formula |
C25H30NO3+ |
| CAS Registry Number |
47608-32-2 |
| SMILES |
C1CC[N+]2(C1)C3CCC2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
